^
    Back
    Association details:
    Biomarker:PTEN mutation
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Fulvestrant +/- Akt inhibition in advanced aromatase inhibitor resistant breast cancer

    Excerpt:
    ...13.Suitable for further endocrine therapy according to the treating clinician.14.Radiological or objective clinical evidence of recurrence or progression on or after the last systemic therapy prior to enrolment.15.Provision of archival tumour sample for PIK3CA mutation and PTEN by IHC testing. ...
    Trial ID:
    2013-000898-68
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    NPJ Breast Cancer
    Title:

    Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

    Published date:
    04/16/2021
    Excerpt:
    In this clinical study, which selectively targeted the aggressive PTEN-mutant ER+ MBC, capivasertib plus fulvestrant was tolerable and clinically active.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1038/s41523-021-00251-7
    Trial ID:
    NCT01226316